Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aehr Test Systems (AEHR) vs Johnson & Johnson (JNJ) Price & Performance

Aehr Test SystemsTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Aehr Test Systems vs Johnson & Johnson — how do they compare? Aehr Test Systems trades at $129 (market cap $3.82B), while Johnson & Johnson trades at $260.77 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 163.9× Aehr Test Systems's market cap, and Johnson & Johnson pays a 2.06% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.

AEHRJNJ
Market Cap
$3.82B$626.09B
Sector
TechnologyHealth
52-Week High
$117.18$267.24
52-Week Low
$17.38$172.78
Enterprise Value
$3.72B$654.37B
Volume
6,156,228
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aehr Test Systems

Aehr Test Systems (AEHR) trades at $129.23, up 21.69% in the last 24 hours, reflecting strong momentum. The stock is technically bullish, trading near resistance at $129, with a high RSI suggesting potential overbought conditions. Fundamentally, the company reported a net loss of $3.91 million for 2025, but has beaten EPS estimates for three consecutive quarters. Recent news highlights a $22 million follow-on order for AI processor wafer-level burn-in systems, signaling robust demand in high-growth sectors.

The outlook is supported by record bookings and a strategic pivot to AI infrastructure, though high valuation multiples and insider selling pose risks. Revenue growth guidance of 160-200% for FY27 offers significant upside potential, but investor caution is warranted due to customer concentration and current unprofitability.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ